Q-omics provides the consensus-scored PAPPA2 profile across patient tissues and cancer cell-line models. PAPPA2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PAPPA2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PAPPA2 protein abundance shows 24,792 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where PAPPA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAPPA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAPPA2 survival associations across molecular data types. PAPPA2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAPPA2 RNA expression–survival associations across cancer types. High PAPPA2 expression shows unfavorable associations in KIRP, STAD, LGG, HNSC, LUSC and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PAPPA2 RNA expression.
This table summarizes PAPPA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PAPPA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAPPA2 shows lower tumor expression in KIRC, KIRP, THCA, UCEC, COAD and BRCA. The KIRC box plot shows higher PAPPA2 RNA expression in normal versus tumor tissue (log2 FC = −3.519, t-test p < 0.001).
This table shows molecular features associated with PAPPA2 in patient tissues and cancer cell lines. In patient samples, PAPPA2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PAPPA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
